Table 4 Milestones in the ACIP recommendations for use of pneumococcal vaccines in adults

2010:

ACIP updates recommendations for PPSV23 in adults – 5 years apart; max 2–3 doses in a lifetime

2011:

FDA approved PCV13 for adults ≥ 50 years – given always 1 year after latest PPSV23 dose^a

2012:

ACIP recommendation published for the use of PCV13 followed by PPSV23 ≥ 8 weeks later in adults ≥ 19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak, and cochlear implant (20 June 2012)^b

2014:

ACIP recommendation published for use of PCV13 in adults ≥ 65 years followed by PPSV23 6–12 months later (13 August 2014)^b

2015:

ACIP changes time interval between PCV13 and PPSV23 in immunocompetent adults ≥ 65 years to one year (4 September 2015)^b

2019:

ACIP reconsiders use of PCV13 in adults ≥ 65 years, recommending a single dose of PPSV23 and not routine use of PCV13 in these adults who do not have an immunocompromising conditions, cerebrospinal fluid leak, or cochlear implant. If a decision to administer PCV13 is made, PCV13 should be administered first, followed by PPSV23 at least 1 year later. If there are immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak, or cochlear implant then PCV13 should be given first followed by PPSV23 ≥ 8 weeks later^b